Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder.
作者信息
Kayser Reilly R, Raskin Marissa, Snorrason Ivar, Hezel Dianne M, Haney Margaret, Simpson Helen Blair
出版信息
J Clin Psychopharmacol. 2020 Mar/Apr;40(2):207-210. doi: 10.1097/JCP.0000000000001179.
Abstract
摘要
相似文献
1
Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder.大麻素增强基于暴露的强迫症心理治疗
J Clin Psychopharmacol. 2020 Mar/Apr;40(2):207-210. doi: 10.1097/JCP.0000000000001179.
2
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.基于暴露的认知行为疗法能否延长静脉注射氯胺酮治疗强迫症的效果？一项开放标签试验。
J Clin Psychiatry. 2016 Mar;77(3):408-9. doi: 10.4088/JCP.15l10138.
3
Does Pregnenolone Enhance Exposure Therapy in Obsessive-Compulsive Disorder? - A Pilot, Interim Report of a Randomized, Placebo-Controlled, Double-Blind Study.孕烯醇酮能否增强强迫症的暴露疗法？——一项随机、安慰剂对照、双盲研究的初步中期报告。
Pharmacopsychiatry. 2016 Mar;49(2):79-81. doi: 10.1055/s-0035-1569371. Epub 2016 Jan 21.
4
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.D-环丝氨酸增强暴露为基础的认知行为疗法治疗焦虑、强迫症和创伤后应激障碍：一项个体参与者数据的系统评价和荟萃分析。
JAMA Psychiatry. 2017 May 1;74(5):501-510. doi: 10.1001/jamapsychiatry.2016.3955.
5
Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.暴露与反应阻止疗法对那些对药物增效策略无反应的成年强迫症患者有帮助。
J Clin Psychiatry. 2015 Dec;76(12):1653-7. doi: 10.4088/JCP.14m09513.
6
Change in obsessive-compulsive symptoms mediates subsequent change in depressive symptoms during exposure and response prevention.在暴露与反应阻止疗法期间，强迫症状的变化介导了随后抑郁症状的变化。
Behav Res Ther. 2015 May;68:76-81. doi: 10.1016/j.brat.2015.03.005. Epub 2015 Mar 13.
7
Sudden gains in the treatment of obsessive-compulsive disorder.强迫症治疗中的突见改善。
Psychother Psychosom. 2012;81(1):44-51. doi: 10.1159/000329995. Epub 2011 Nov 22.
8
Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.增强5-羟色胺再摄取抑制剂治疗强迫症：患者对利培酮的偏好并不限制暴露与仪式行为阻止法的有效性。
Psychother Psychosom. 2016;85(5):314-6. doi: 10.1159/000445356. Epub 2016 Aug 12.
9
Sex, drugs, and adult neurogenesis: sex-dependent effects of escalating adolescent cannabinoid exposure on adult hippocampal neurogenesis, stress reactivity, and amphetamine sensitization.性、毒品和成人神经发生：青少年大麻素暴露不断升级对成年海马神经发生、应激反应和安非他命敏化的性别依赖性影响。
Hippocampus. 2014 Mar;24(3):280-92. doi: 10.1002/hipo.22221. Epub 2013 Nov 13.
10
The Impact of Δ9-THC on the Psychological Symptoms of Anorexia Nervosa: A Pilot Study.Δ9-四氢大麻酚对神经性厌食症心理症状的影响：一项初步研究。
Isr J Psychiatry. 2017;54(3):44-51.
引用本文的文献
1
Hereditary Patterns and Genetic Associations in Obsessive-Compulsive Disorder (OCD): Neuropsychiatric Insights, Genetic Influences, and Treatment Perspectives.强迫症（OCD）的遗传模式与基因关联：神经精神学见解、基因影响及治疗前景
Curr Gene Ther. 2025;25(3):257-316. doi: 10.2174/0115665232316708240828063527.
2
Cannabinoids in the Treatment of Selected Mental Illnesses: Practical Approach and Overview of the Literature.大麻素类药物治疗特定精神疾病：实用方法和文献综述。
Pharmacopsychiatry. 2024 May;57(3):104-114. doi: 10.1055/a-2256-0098. Epub 2024 Mar 1.
3
Repeated Δ-9-Tetrahydrocannabinol administration dose dependently increases stablished schedule-induced drinking.反复给予 Δ-9-四氢大麻酚给药剂量依赖性地增加既定的条件性饮水。
Psychopharmacology (Berl). 2024 Jun;241(6):1277-1286. doi: 10.1007/s00213-024-06563-3. Epub 2024 Feb 28.
4
Selective alterations of endocannabinoid system genes expression in obsessive compulsive disorder.强迫症中环核苷酸系统基因表达的选择性改变。
Transl Psychiatry. 2024 Feb 26;14(1):118. doi: 10.1038/s41398-024-02829-8.
5
Use of Selective Alternative Therapies for Treatment of OCD.使用选择性替代疗法治疗强迫症。
Neuropsychiatr Dis Treat. 2023 Apr 5;19:721-732. doi: 10.2147/NDT.S403997. eCollection 2023.
6
Genetic influences on the interplay between obsessive-compulsive behavior symptoms and cannabis use during adolescence.遗传因素对青少年强迫行为症状与大麻使用之间相互作用的影响。
J Adolesc. 2023 Apr;95(3):427-436. doi: 10.1002/jad.12125. Epub 2022 Nov 28.
7
Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.医用大麻素：基于药理学的系统评价和荟萃分析，涵盖所有相关医学适应证。
BMC Med. 2022 Aug 19;20(1):259. doi: 10.1186/s12916-022-02459-1.
8
Medicinal Cannabis and Central Nervous System Disorders.药用大麻与中枢神经系统疾病
Front Pharmacol. 2022 Apr 21;13:881810. doi: 10.3389/fphar.2022.881810. eCollection 2022.
9
Patterns of Cannabis Use Among Individuals with Obsessive-Compulsive Disorder: Results from an Internet Survey.强迫症患者的大麻使用模式：一项网络调查结果
J Obsessive Compuls Relat Disord. 2021 Jul;30. doi: 10.1016/j.jocrd.2021.100664. Epub 2021 Jul 13.
10
Cannabis Use in People With Obsessive-Compulsive Symptomatology: Results From a Mexican Epidemiological Sample.有强迫症状的人群中使用大麻的情况：来自墨西哥一项流行病学样本的结果。
Front Psychiatry. 2021 May 10;12:664228. doi: 10.3389/fpsyt.2021.664228. eCollection 2021.
本文引用的文献
1
The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?内源性大麻素系统：强迫症的新治疗靶点？
Cannabis Cannabinoid Res. 2019 Jun 14;4(2):77-87. doi: 10.1089/can.2018.0049. eCollection 2019.
2
Current understanding of fear learning and memory in humans and animal models and the value of a linguistic approach for analyzing fear learning and memory in humans.目前对人类和动物模型中恐惧学习和记忆的理解，以及采用语言分析方法分析人类恐惧学习和记忆的价值。
Neurosci Biobehav Rev. 2019 Oct;105:136-177. doi: 10.1016/j.neubiorev.2019.03.015. Epub 2019 Apr 7.
3
Exposure and response prevention for obsessive-compulsive disorder: A review and new directions.强迫症的暴露与反应阻止疗法：综述与新方向
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S85-S92. doi: 10.4103/psychiatry.IndianJPsychiatry_516_18.
4
Neuroscientifically Informed Formulation and Treatment Planning for Patients With Obsessive-Compulsive Disorder: A Review.神经科学启发的强迫症患者制定方案和治疗计划：综述。
JAMA Psychiatry. 2018 Oct 1;75(10):1081-1087. doi: 10.1001/jamapsychiatry.2018.0930.
5
Highway to hell or magic smoke? The dose-dependence of Δ-THC in place conditioning paradigms.通往地狱之路还是神奇烟雾？Δ-四氢大麻酚在位置条件反射范式中的剂量依赖性。
Learn Mem. 2018 Aug 16;25(9):446-454. doi: 10.1101/lm.046870.117. Print 2018 Sep.
6
Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation.健康与疾病中的大麻素：在代谢综合征和神经炎症中的药理潜力。
Horm Mol Biol Clin Investig. 2018 Mar 30;36(2):/j/hmbci.2018.36.issue-2/hmbci-2018-0013/hmbci-2018-0013.xml. doi: 10.1515/hmbci-2018-0013.
7
Neural basis of impaired safety signaling in Obsessive Compulsive Disorder.强迫症中安全信号受损的神经基础。
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3216-3221. doi: 10.1073/pnas.1609194114. Epub 2017 Mar 6.
8
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.D-环丝氨酸增强暴露为基础的认知行为疗法治疗焦虑、强迫症和创伤后应激障碍：一项个体参与者数据的系统评价和荟萃分析。
JAMA Psychiatry. 2017 May 1;74(5):501-510. doi: 10.1001/jamapsychiatry.2016.3955.
9
Endocannabinoid Modulation of Orbitostriatal Circuits Gates Habit Formation.内源性大麻素对眶额纹状体回路的调节控制习惯形成。
Neuron. 2016 Jun 15;90(6):1312-1324. doi: 10.1016/j.neuron.2016.04.043. Epub 2016 May 26.
10
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.基于暴露的认知行为疗法能否延长静脉注射氯胺酮治疗强迫症的效果？一项开放标签试验。
J Clin Psychiatry. 2016 Mar;77(3):408-9. doi: 10.4088/JCP.15l10138.
Zotero 插件